Experimental infection and protection against ... - TI Pharma

26 Chapter 1
67. Covell G, Nicol WD. Clinical, chemotherapeutic and immunological studies on
induced malaria. Br Med Bull 1951; 8:51-55.
68. Campbell CC, Collins WE, Nguyen-Dinh P, Barber A, Broderson JR. Plasmodium
falciparum gametocytes from culture in vitro develop to sporozoites that are
infectious to primates. Science 1982; 217:1048-1050.
69. Ponnudurai T, Lensen AH, van Gemert GJ, Bensink MP, Bolmer M, Meuwissen
JH. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes.
Parasitology 1989; 98 Pt 2:165-173.
70. Ifediba T, Vanderberg JP. Complete in vitro maturation of Plasmodium
falciparum gametocytes. Nature 1981; 294:364-366.
71. Church LW, Le TP, Bryan JP et al. Clinical manifestations of Plasmodium
falciparum malaria experimentally induced by mosquito challenge. J Infect Dis
1997; 175:915-920.
72. Epstein JE, Rao S, Williams F et al. Safety and clinical outcome of experimental
challenge of human volunteers with Plasmodium falciparum-infected
mosquitoes: an update. J Infect Dis 2007; 196:145-154.
73. Verhage DF, Telgt DS, Bousema JT et al. Clinical outcome of experimental
human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J
Med 2005; 63:52-58.
74. Hermsen CC, Telgt DS, Linders EH et al. Detection of Plasmodium falciparum
malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol
2001; 118:247-251.
75. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW.
Testing vaccines in human experimental malaria: statistical analysis of
parasitemia measured by a quantitative real-time polymerase chain reaction.
Am J Trop Med Hyg 2004; 71:196-201.
76. Bejon P, Andrews L, Andersen RF et al. Calculation of liver-to-blood inocula,
parasite growth rates, and preerythrocytic vaccine efficacy, from serial
quantitative polymerase chain reaction studies of volunteers challenged with
malaria sporozoites. J Infect Dis 2005; 191:619-626.
77. Spring MD, Cummings JF, Ockenhouse CF et al. Phase 1/2a study of the malaria
vaccine candidate apical membrane antigen-1 (AMA-1) administered in
adjuvant system AS01B or AS02A. PLoS One 2009; 4:e5254.
78. Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with
a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008; 3:e1493.
79. Genton B, D'Acremont V, Lurati-Ruiz F et al. Randomized double-blind
controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to
protect against challenge with P. falciparum. Vaccine 2010; 28:6573-6580.
80. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant
circumsporozoite protein vaccine regimens against experimental Plasmodium
falciparum malaria. J Infect Dis 2001; 183:640-647.
81. Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine 2010;
28:4880-4894.
82. Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3
month and 0, 7, and 28 day immunization schedules of malaria vaccine